For instance, FLT3 mutations in AML promote proliferation through mTOR signaling, whereas BCR-ABL kinase in CML activates the PI3K/Akt/mTOR pathway by binding to the p85 PI3K regulatory subunit [11,12]. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.